

Technology Appraisal Committee B Interests Register

Topic: Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

Publication Date: Tbc.

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|----------------------|-----------------|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------------------------------------|
| Peter Wheatley-Price | TAC B Member | Direct Financial | Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating relapsed or refractory multiple myleoma (TA505). It has also been appraised to enable exit the CDF (ID1635). | 10/12/2023 | It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal. |
| Rakesh Popat | Clinical Expert | Direct – financial Indirect - Financial | Consultancy: GSK, Janssen, Sanofi, Galapagos, Roche Honoraria: Abbvie, Janssen, GSK, Pfizer, BMS. Research Support (to institution): GSK, Pfizer. Travel Support: Janssen, GSK Leeds University has received grant funding for the ProMMise trial that I lead | 08/01/2024 | It was agreed that Rakesh Popat's declaration would not prevent him from providing expert advice to the committee. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|-----------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------------------------------------------------|
| Karthik Ramasamy | Clinical Expert | Direct – Financial | Direct – financial - Served as an advisor and has received speaker honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Celgene (Bristol Myers Squibb), EUSA Pharma/ Recordati, Glaxo Smith Kline, Janssen, Karyopharm, Oncopeptides, Pfizer, Sanofi, and Takeda. Conference Travel grants from Takeda, Janssen, Menarini Stemline | 08/01/2024 | It was agreed that Karthik Ramasamy's declaration would not prevent her from providing expert advice to the committee. |
| | | Indirect - Financial | Grants to Institution from Takeda, GSK, Amgen, Janssen | | |
| Scott Purdon | Patient expert | | We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849). | 08/01/2024 | It was agreed that Scott Purdon's declaration would not prevent him from providing expert advice to the committee. |
| Amy Capper | Patient Expert | Indirect – Financial | We have received funding for a specific research project from the manufacturer of the technology in | 08/01/2024 | It was agreed that Amy Capper's declaration would not prevent her from |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|----------------|-------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------------------------------------------------------------------------------------------------------|
| | | | the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849). | | providing expert advice to the committee. |
| David Robinson | Patient Expert | Indirect – Financial | We have received funding for a specific research project from the manufacturer of the technology in the last 12 months (£19,259). 2022. In 2022, 5.7% of Myeloma UK's income came from pharmaceutical companies (£298,849). | 08/01/2024 | It was agreed that David Robinson's declaration would not prevent him from providing expert advice to the committee. |